All.Can – changing cancer care together

All.Can is an international initiative working to improve efficiency in cancer care by focusing on what really matters to patients. For more information, visit the All.Can website.

Context

With the growing prevalence of cancer and ongoing pressures on healthcare budgets, there is a challenge to find sustainable solutions and improve efficiency in cancer care.

Current approaches to cancer care may not be sufficient for tomorrow. We must find new ways to maximise resources, ensuring that the needs of the patient are always at the core of cancer care. This means eliminating elements that bring little or no benefit to patients while prioritising interventions that confer meaningful benefits to patients.

%

20% of healthcare spending is estimated to be wasted on ineffective interventions

Reducing inefficiency could lead to an average gain of 2 life years in industrialised countries

1 in 3 cancer patients don’t receive pain medication appropriate to their pain level

What we achieved

HPP acts as secretariat for All.Can, providing operational support to its steering committee and members. Members come from all sectors relevant to cancer care, including patient organisations, policymakers, healthcare professionals, research and industry representatives.

In addition to All.Can international, there are national All.Can initiatives across Europe, Australia and Canada, with many more in development around the world. They are represented on the international initiative through the National Initiatives Working Group.

All.Can published a policy report in January 2017, which was adapted into a peer-reviewed paper published in the Journal of Cancer Policy. There have been several further All.Can publications and events, including posters at the European Society for Medical Oncology (ESMO) Congress, sessions at the European Health Forum Gastein in 2017 and 2018, and articles in The Parliament Magazine, Open Access Government, Brain Tumour magazine and EuroHealth.

In 2018, All.Can conducted a patient survey across 10 countries to gain patient insights on where inefficiency occurs across the cancer care pathway. The findings were published in July 2019, with coverage in numerous news and healthcare publications including an opinion piece in BMJ.

All.Can is a collaborating partner of iPAAC, the Joint Action on Cancer Control.

For more information, visit the All.Can website.

Key partners and stakeholders

  • Matti Aapro, Clinique de Genolier, Switzerland
  • Tit Albreht, Institute of Public Health, Slovenia
  • Neil Bacon, International Consortium for Health Outcomes Measurement
  • Kathy Barnard, Save Your Skin Foundation
  • Antonella Cardone, European Cancer Patient Coalition
  • Szymon Chrostowski, Polish Cancer Patient Coalition
  • David Duplay, Healtheo360
  • Alex Filicevas, European Cancer Patient Coalition
  • Pascal Garel, European Hospital and Healthcare Federation (HOPE)
  • Stefan Gijssels, Digestive Cancers Europe
  • Rainer Hess, GVG-Committee on Health Goals
  • Matthew Hickey, Intacare International Ltd
  • Petra Hoogendoorn, Goings-On
  • Vivek Muthu, Marivek Healthcare Consulting, UK
  • Kathy Oliver, International Brain Tumour Alliance
  • Richard Price, European CanCer Organisation (ECCO)
  • Natalie Richardson, Save Your Skin Foundation
  • Christobel Saunders, University of Western Australia
  • Thomas Szucs, University of Basel
  • Jan van Meerbeeck, Antwerp University Hospital
  • Andy Whitman, Varian
  • Lieve Wierinck, Former MEP
  • Luigi Antoniazzi, Baxter
  • Aleksandra Krygiel-Nael, Johnson & Johnson
  • Titta Rosvall-Puplett, Bristol-Myers Squibb
  • Karin Steinmann, Amgen
  • Matthijs Van Meerveld, MSD
The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Roche (major sponsor), Amgen, MSD and Johnson & Johnson (sponsors), and Baxter (contributor), with additional non-financial (in kind) support from Helpsy, Intacare and Goings-On.